Aims Worldwide observational studies are evidencing discordance between guidelines and
real‐world practice regarding direct oral anticoagulant drug (DOAC) doses. This systematic …

Background: Prescriptions of off-label under-and overdosing of direct oral anticoagulants
(DOACs) are common for patients with atrial fibrillation, but their efficacy and safety remain …

Background: The use of direct oral anticoagulant (DOAC) off-label doses in atrial fibrillation
(AF) patients may result in poor clinical outcomes. However, the true prevalence remains …

Aims The aim of this study was to compare the clinical effectiveness and safety of direct oral
anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice …

Abstract Background Direct oral anticoagulants (DOACs) reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation but may result in serious …

Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Background: Off-label dosing of direct oral anticoagulants (DOACs) is encountered clinically
among patients with atrial fibrillation (AF), although data on the clinical outcomes of over …

Background The recommended doses for direct oral anticoagulants (DOACs) to prevent
stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) are described in …

Direct Oral Anticoagulants (DOACs) require dose adjustment based on specific patient
characteristics, making them prone to incorrect dosing. The current study aimed to evaluate …

Background: The current status and outcomes of direct oral anticoagulant (DOAC) use have
not been widely evaluated in unselected patients with atrial fibrillation (AF) in the real world …